PMC10075310_01
Timeline of the case presentation.
fneur-14-1060180-g0001.jpg
PMC10075310_01_fneur-14-1060180-g0001.jpg
F1
Standard radiation therapy was started on 25 November 2018, following which temozolomide (75 mg/m2/day) was taken 1 h before the initiation of radiation therapy for the first week and then continued separately for 54 days until 20 January 2019 (Figure 1). Eventually, the patient passed away on 16 July 2020 (progression-free survival (PFS) = 293 days, overall survival (OS) = 513 days) (Figure 1).
(A, B) The HEK 293T cell lines transfected with the calcium phosphate method, taken from an inverted microscope (10x), which shows (A) visible light and (B) fluorescent light. (C, D) The transduced mesenchymal stem cells originated from an inverted microscope (10x), which indicates (C) visible light and (D) fluorescent light.
fneur-14-1060180-g0002.jpg
PMC10075310_01_fneur-14-1060180-g0002.jpg
F2
Tat), and pMD2 plasmid [containing glycoprotein (G) of vesicular stomatitis viruses (VSVs)] by calcium phosphate reagent (Sigma Aldrich, USA) (Figure 2). Following the titration of recombinant viruses, the mesenchymal stem cells were transduced with a certain amount of the virus (MOI 40) (Figure 2).
Cell morphology assay of MSCs derived from the patient's bone marrow. The spindle-shaped MSCs are visible at several growth rates.
fneur-14-1060180-g0003.jpg
PMC10075310_01_fneur-14-1060180-g0003.jpg
F3
The cell population indicated the positive expression of CD44, CD90, CD73, and CD105 (94.8, 90.6, 95.1, and 52.5%, respectively); however, CD45 were not expressed (< 0.08%) (Figures 3, 4).
Flow cytometry assay indicated the positive expression of CD44, CD90, CD73, and CD105 (94.8, 90.6, 95.1, and 52.5%, respectively), and CD45 were not expressed (<0.08%).
fneur-14-1060180-g0004.jpg
PMC10075310_01_fneur-14-1060180-g0004.jpg
F4
The cell population indicated the positive expression of CD44, CD90, CD73, and CD105 (94.8, 90.6, 95.1, and 52.5%, respectively); however, CD45 were not expressed (< 0.08%) (Figures 3, 4).
Magnetic resonance imaging of the patient in (A) November 2018 showing left frontal lesion and evidence of craniotomy related to previous surgery for parietal lesion 1 month earlier; (B) February 2019 with no obvious evidence of recurrence at the time of injection to the frontal focus; (C) December 2019 showing first evidence of recurrence of tumor mostly at the parietal site; (D) March 2020 showing left frontal focus had no prominent recurrence; however, the size of the left parietal focus increased and extended to the contralateral hemisphere through the corpus callosum.
fneur-14-1060180-g0005.jpg
PMC10075310_01_fneur-14-1060180-g0005.jpg
F5
On the last radiological follow-up (on 18 March 2020), the frontal focus showed no prominent recurrence; however, the size of the parietal focus increased and extended to the contralateral hemisphere through the corpus callosum (Figure 5).